patent/TN-SN06016-A1

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TN-SN06016-A1

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a5754a1fdd7e7e3012461aa300f44675
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-284 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2866 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
classificationIPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22
filingDate	2006-01-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2e43d57556e112f786c751b250353406 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_429cbf276cfa2e280a4f0eed90844563 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2894c54e6e3f4d4cce3c96b44e0005f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2d06fa63a2dbe960f70fc8d12ea6c26f
publicationDate	2007-10-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	TN-SN06016-A1
titleOfInvention	Modified-release tablet of bupropion hydrochloride
abstract	A modified-release tablet of bupropion hydrochloride comprising (i) a core comprising an effective amount of bupropion hydrochloride, a binder, a lubricant; and (ii) a control releasing coat surrounding said core; and (iii) Wellbutrin © or Zyban® / Wellbutrin®SR tablets, a soluble barrier surrounding said control releasing coat, the modified-release tablet is bioequivalent.
priorityDate	2003-08-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419532742

Total number of triples: 31.